Tom Macleod

Tom Macleod

Auto-generated profile, based on publicly available information

Tom Macleod

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds , Leeds

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
CBCharlie Bridgewood
Charlie Bridgewood
MWMiriam Wittmann
Miriam Wittmann
TMTom Macleod
Tom Macleod
Abdulla WatadAbdulla Watad
Abdulla Watad
DNDarren Newton
Darren Newton
DMDennis McGonagle
Dennis McGonagle
Dupilumab, an IL-4/IL-13 receptor blocker, has been linked to emergent seronegative inflammatory arthritis and psoriasis that form part of the spondyloarthropathy spectrum. We systematically investigated patterns of immune disorders, including predominantly T helper 17‒(spondyloarthropathy pattern) and T helper 2‒mediated disorders and humoral autoimmune pattern diseases, using VigiBase, the World Health Organization's global pharmacovigilance of adverse drug reactions. Several bioinformatics databases and repositories were mined to couple dupilumab-related immunopharmacovigilance with molecular cascades relevant to reported findings. A total of 37,848 dupilumab adverse drug reaction cases were reported, with skin, eye, and musculoskeletal systems most affected. Seronegative arthritis (OR = 9.61), psoriasis (OR = 1.48), enthesitis/enthesopathy (OR = 12.65), and iridocyclitis (OR = 3.77) were highly associated. However, ankylosing spondylitis and inflammatory bowel disease were not conclusively associated. Overall, classic polygenic humoral‒mediated autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus were not associated with dupilumab use. Pathway analysis identified several biological pathways potentially involved in dupilumab‒associated adverse drug reactions, including the fibroblast GF receptor (in particular, FGFR2) pathway. MicroRNAs analysis revealed the potential involvement of hsa-miR-21-5p and hsa-miR-335-5p. In conclusion, IL-4/IL-13 blockers are not unexpectedly protective against humoral autoimmune diseases but dynamically skew immune responses toward some IL-23/IL-17 cytokine pathway‒related diseases. IL-4/13 axis also plays a role in homeostatic tissue repair and we noted evidence for a link with ocular and arterial pathology.

22 April 2016 in Scientific Reports
Verified
Journal Article
Open access
TMTom Macleod
Tom Macleod
RDRosella Doble
Rosella Doble
DMDennis McGonagle
Dennis McGonagle
CWChristopher W. Wasson
Christopher W. Wasson
AAAdewonuola Alase
Adewonuola Alase
MWMiriam Wittmann
Miriam Wittmann
The interleukin-36 receptor antagonist (IL-36Ra) which regulates IL-36α, -β and -γ is linked to psoriatic inflammation, especially loss-of-function mutations in pustular psoriasis subtypes. As observed with other IL-1 superfamily proteins, the IL-36 members require N-terminal cleavage for full biological activity but the mechanisms of IL-36Ra activation remain poorly defined. Using different blood leukocyte and skin resident cell preparations and recombinant proteins, we have identified that neutrophil elastase, but not other neutrophil derived proteases, cleaves IL-36Ra into its highly active antagonistic form. The activity of this processed form of IL-36Ra was confirmed in human primary dermal fibroblasts and keratinocytes and in skin equivalents. A significant dose dependent reduction of IL-36γ induced IL-8 and chemokine ligand 20 (CCL20) levels were detected following addition of the cleaved IL-36Ra compared to full length IL-36Ra. By activating IL-36Ra, the neutrophil derived protease can inhibit IL-36 induced chemokine production, including IL-8 and CCL20 and reduce further inflammatory cell infiltration. These findings strongly indicate neutrophil elastase to be a key enzyme in the biological function of IL-36Ra and that neutrophils can play a regulatory role in psoriatic inflammation with regard to balancing the pro-inflammatory activity of IL-36.

2 November 2023 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
DMDennis McGonagle
Dennis McGonagle
PDPaula David
Paula David
TMTom Macleod
Tom Macleod
AWAbdulla Watad
Abdulla Watad

22 September 2022
Verified
Conference Paper
Closed access
TMTom Macleod
Tom Macleod
SDSayam Dubash
Sayam Dubash
ABAnna Berekmeri
Anna Berekmeri
XVXabier Vegas
Xabier Vegas
GAGiuseppina Abignano
Giuseppina Abignano
MWMiriam Wittmann
Miriam Wittmann
Elafin, an elastase specific protease inhibitor, is well described to be upregulated in lesional psoriatic skin. Elastase is active in antimicrob | POSTER

22 July 2026 in Rheumatology
Verified
Journal Article
Open access
TMTom Macleod
Tom Macleod
SDSayam R Dubash
Sayam R Dubash
IHIsabel Hyde
Isabel Hyde
XMXabier Michelena
Xabier Michelena
ABAnna Berekmeri
Anna Berekmeri
MWMiriam Wittmann
Miriam Wittmann
Objectives: Identifying which patients with psoriasis (PsO) may develop PsA is a research priority. We have previously shown that elafin, along with IL-36γ, are excellent cutaneous biomarkers for PsO. The protease inhibitor elafin and its target protease, neutrophil elastase (NE), can be detected in both serum and epidermal samples. Our aims were to assess whether known PsO biomarkers are expressed differentially in patients affected by plaque PsO with and without PsA. Methods: Protein expression of NE and elafin were analysed in matched epidermal samples and serum of PsO, PsA patients and healthy controls. Findings were validated in independent PsA and arthritis cohorts. Results: The ratio between NE and elafin differed significantly between PsO and PsA patients. Expression of elafin was reduced in PsA samples as compared with plaque PsO patients. The ratio of NE to secretory leucocyte protease inhibitor was also increased in PsA as compared with PsO patients with no PsA, healthy controls and other arthritis patients. Conclusions: PsA patients show a reduced NE inhibitor expression in both the skin and blood compartment compared with those with plaque PsO only. This may suggest differences in the ability to regulated neutrophil activity in PsA patients.